Janssen awarded breakthrough therapy designation for Genmab bone marrow cancer drug

The US authorities see potential for a groundbreaking treatment in talquetamab, which is being developed by Janssen based on Genmab’s technology.

Photo: PR / Genmab

Drug candidate talquetamab could potentially significantly improve treatment options for people with recurring or treatment-resistant bone marrow cancer, the FDA has concluded.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs